Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

"We are excited for Vtama cream to benefit from Organon's commercial scale. We believe they have the capabilities and reach to ensure patients globally can access this important medicine," said ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The massive amount comprises an up-front $175 million payment, along with a potential $75 million regulatory milestone and up to $950 million ...

"Additionally, we are excited for VTAMA cream to benefit from Organon's commercial scale. We believe they have the capabilities and reach to ensure patients globally can access this important medicine ...